

History of Li-Fraumeni Syndrome (LFS) and the LFS Association

Founding Fathers



Dr. Frederick Li

Dr. Joseph Fraumeni

1969

Two NIH scientists, **Drs. Frederick Li and Joseph Fraumeni**, report a rare familial syndrome of multiple cancers in children and young adults, including sarcomas, breast cancer and other tumors. This discovery of childhood tumors and cancer-prone families occurs at a time when little attention was given to the role of genetic susceptibility in cancer.

1979

Drs. David Lane and Arnold Levine co-discover the **TP53 tumor suppressor gene**, which, over time, is recognized to be the cause of a wide range of cancers. **TP53** is currently one of the most studied genes in the world.

1982

Researchers in the United Kingdom are the first to coin the name "**Li-Fraumeni syndrome**."

1988

Drs. Judy Garber, Li, Fraumeni and colleagues document the **elevated risk of subsequent cancers in 24 families with LFS**, note the especially high risk for breast cancer in young women, and propose the first "classical" definition of LFS based on clinical and familial criteria. **Drs. Louise Strong** in Houston, **Jillian Birch** in Manchester, and **Ros Eeles** in London provide important insights into the LFS component tumors and mode of inheritance.

1990

A multi-institutional team led by **Drs. David Malkin and Stephen Friend** in Boston discover that **inherited ("germline") mutations of TP53 are the primary cause of LFS**. This opens the door for predictive and diagnostic genetic testing.

1992

Recommendations that address clinical, psychosocial, ethical, economic and legal ramifications of genetic testing in LFS with applications to other genetic disorders, particularly in children, are published.

1992

A team lead by **Drs. Alan Balmain and Larry Donehower** in Houston create the **first p53-deficient mouse**. It has a very high incidence of cancer that are subsequently shown to occur earlier when the mice are exposed to radiation.

1998

A team led by **Drs. Li and Fraumeni** document the **elevated risk of subsequent cancers** in LFS patients, even outside the radiation field of a primary malignancy.

2001

A collaboration of investigators in Brazil and Memphis **describe a unique germline TP53 mutation in children with adrenal cortical cancer in southeastern Brazil**.

2004

Teams led by **Drs. Gigi Lozano** in Houston and **Tyler Jacks** in Boston describe the **first TP53 mutant mouse models of LFS**, which are subsequently used to better understand how cancers develop and progress.

2016

The **LFS Medical Advisory Board** is formed, followed shortly thereafter with the formation of the **LFS Genetic Counseling Advisory Group**.

2015

Researchers in France, led by **Drs. Thierry Frebourg and Laurence Brugieres**, update the "**Chompret criteria**" further refining the clinical and familial characteristics widely used to help identify potential carriers and facilitate the diagnosis of LFS.

2010

NIH convenes a meeting of LFS researchers and, for the first time, LFS patients and family members, to generate plans for an international and multidisciplinary alliance of scientists, clinicians, psychologists and genetic counselors - the **Li-Fraumeni Exploratory (LiFE) Consortium**. At this meeting, families form the **LFS Association (LFSA)** to partner with LiFE and best meet the needs of the LFS patient community.

2007

Dr. Maria Isabel Achatz provides evidence that the "**Brazilian**" **TP53 mutation** is a "**founder mutation**" derived from a common ancestor migrating long ago from Portugal. The spectrum of cancers in these families resembles those with "classic" LFS.

2017

The **LFS Association** pilots its first **Youth Workshop with teenage participants from around the world**, and launches international chapters in Germany, Saudi Arabia, and the Netherlands, in addition to Canada, Australia/New Zealand, and Brazil.

2017

New screening recommendations are published based on the modification of the "Toronto protocol". Comprehensive consideration is given to the impact on patients to maximize participation in early tumor detection screening.